Caligan Partners LP
Caligan Partners LP reported 26 holdings worth US$1.63B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Caligan Partners LP reported 26 holdings worth US$1.63B as of Sep 30, 2026. Largest: Revolution Medicines, Inc., Liquidia Corporation and Abivax SA. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 26
- Value as reported
- US$1.63B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Revolution Medicines, Inc. | 1.96M | US$403M | 24.6% |
| Liquidia Corporation | 8.12M | US$246M | 15.0% |
| Abivax SA | 1.56M | US$154M | 9.4% |
| Vaxcyte, Inc. | 2.19M | US$125M | 7.6% |
| Exelixis, Inc. | 1.55M | US$90.7M | 5.6% |
| Tango Therapeutics, Inc. | 2.5M | US$62.4M | 3.8% |
| ADMA Biologics Inc | 5.88M | US$58.9M | 3.6% |
| Immunocore Holdings plc | 1.67M | US$50.6M | 3.1% |
| Avalo Therapeutics, Inc. | 3.27M | US$50.1M | 3.1% |
| LB Pharmaceuticals Inc | 1.51M | US$49.6M | 3.0% |
| Viridian Therapeutics, Inc. | 2.19M | US$45.2M | 2.8% |
| Vor Biopharma Inc. | 1.93M | US$36.7M | 2.2% |
| Inventiva SA | 9.19M | US$33.9M | 2.1% |
| Opus Genetics, Inc. | 5.96M | US$28.9M | 1.8% |
| Aura Biosciences, Inc. | 4.59M | US$28.8M | 1.8% |
| Anika Therapeutics Inc. | 1.44M | US$28.2M | 1.7% |
| SAB Biotherapeutics, Inc. | 8.74M | US$27.7M | 1.7% |
| Sagimet Biosciences Inc. - Series A | 2.79M | US$27.6M | 1.7% |
| Sensei Biotherapeutics, Inc. | 890K | US$26.5M | 1.6% |
| Tyra Biosciences, Inc. | 911K | US$19.9M | 1.2% |
| Obsidian Therapeutics, Inc. | 886K | US$12.2M | 0.74% |
| Eupraxia Pharmaceuticals, Inc. | 1.16M | US$10.6M | 0.65% |
| Artiva Biotherapeutics, Inc. | 1.48M | US$10.5M | 0.65% |
| Verrica Pharmaceuticals Inc. | 924K | US$4.43M | 0.27% |
| TCGX Acquisition Corp. | 200K | US$2.5M | 0.15% |
| Cellectar Biosciences, Inc. | 470K | US$865K | 0.05% |
| MBX Biosciences, Inc. | 0 | US$0 | 0.00% |
| Xenon Pharmaceuticals Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related